3 min read
Global Spotlight Shines on mRNA Thanks to Pfizer, BioNTech COVID-19 Vaccine Candidate
By Debra Valsamis on Nov 11, 2020 11:05:03 AM
In the science shot heard ‘round the world, Pfizer and BioNTech announced Monday that their vaccine candidate (aka “BNT162b2”) appears to be more than 90% effective in preventing SARS-CoV-2 among those without evidence of prior infection. And since that news broke on the same day that the number of confirmed U.S. cases of COVID-19 crossed yet another grim threshold — 10 million infected — it couldn’t have come at a better time.
Topics: Insights SARS-CoV-2 COVID-19 mRNA
Filter by Keyword
- Insights (34)
- Events (16)
- COVID-19 (15)
- SARS-CoV-2 (14)
- News (11)
- Molecular Modeling (9)
- Transgenic Animals (6)
- Antibody Discovery (4)
- Therapeutic Targets (3)
- 25th Anniversary (2)
- Omicron (2)
- Therapeutic Monoclonal Antibodies (2)
- Antibody Generation (1)
- Antibody-Drug Conjugate (ADC) (1)
- Antigen (1)
- CAR-T (1)
- Cell Fusion (1)
- Cell therapy (1)
- Functional Assays (1)
- Harbour (1)
- Hybridoma (1)
- IgG purification (1)
- Immunoassays (1)
- Immunogens (1)
- Lambda Light Chain (1)
- Lambda Mouse (1)
- MAbExpress (1)
- Monoclonal (1)
- OmniRat (1)
- Peptides (1)
- Syngeneic (1)
- Target Analysis (1)
- Transgenic H2L2 Mice (1)
- Women In Bio (1)
- igG (1)
- mRNA (1)